Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Robert Driscoll maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $60 price target. Driscoll, a 5-star analyst in the Healthcare sector, also covers Replimune Group and Kura Oncology. Additionally, Mizuho Securities issued a Buy rating for IDYA with a $50 price target.
In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on IDEAYA Biosciences, with a price target of $60.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Driscoll is a 5-star analyst with an average return of 12.6% and a 47.47% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Replimune Group, Kura Oncology, and IDEAYA Biosciences.
In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $50.00 price target.